Full Press Release Details
IRIDEX Reports 2013 First Quarter Results
Profits Increase as Commercial Progress and Operational Streamlining Continue
MOUNTAIN VIEW, Calif., May 2, 2013 IRIDEX Corporation (Nasdaq: IRIX) today reported financial results for the first
quarter ended March 30, 2013.
CEO William M. Moore said,
We demonstrated good execution in the first quarter as the Company increased revenues and profits. In addition to these commercial and operational gains, we completed the successful product launch of TxCell , our high speed scanning laser
delivery system, and concluded negotiation of a beneficial selling and supply chain agreement with Peregrine Surgical. Of particulate note, the percentage of customers ordering new lasers with MicroPulse in the first quarter was approximately
double that seen in last year s period, giving us one more indication that we are edging towards a technology-driven tipping point in the market.
Moore continued, We will look to grow and increase profitability, invest in products that our customers want and that can be delivered to the market rapidly, and be opportunistic in acquiring or
partnering with ophthalmic companies that have developed excellent technologies. Peregrine is a great example of such a partnership, as it allows us to market additional consumable products at different price points. The relationship should lower
our supply chain costs and we are already, jointly, working on new product initiatives in the high-margin consumable product category.
The preceding commentary relates to the results of the Company s continuing ophthalmology business. In February 2012, the Company sold its aesthetics laser business and the financial statements
reflect the results of its aesthetics laser business as discontinued operations.
Recent Business Highlights
IRIDEX management will conduct a conference call later today, Thursday, May 2 at 5:00 p.m. Eastern Time. Interested parties may
access the live conference call via telephone by dialing (877) 941-2927 (U.S.) or (480) 629-9725 (International) and quoting Conference ID 4615855, or by visiting the Company s website at www.iridex.com. A telephone replay will
be available beginning on Thursday, May 2, 2013 through Thursday, May 9, 2013 by dialing (800) 406-7325 (U.S.) or (303) 590-3030 (International) and entering Access Code 4615855. In addition, later today an archived version of
the webcast will be available on the Company s website at www.iridex.com.
IRIDEX Corporation was founded in 1989 and is a worldwide leader in developing, manufacturing, and marketing innovative and versatile
laser-based medical systems, delivery devices and consumable instrumentation for the ophthalmology market. We maintain a deep commitment to the success of our customers, with comprehensive technical, clinical, and service support programs. IRIDEX is
dedicated to a standard of excellence, offering superior technology for superior results. IRIDEX products are sold in the United States through a direct sales force and internationally through a combination of a direct sales force and a network of
approximately 70 independent distributors into over 100 countries. For further information, visit the Company s website at http://www.iridex.com/.
Safe Harbor Statement
This announcement contains forward-looking
statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Act of 1934, as amended, relating to the size and growth of and trends in the markets in which the Company operates,
including market adoption of new technologies; the success of the Company s development, marketing and sales efforts, including the adoption of MicroPulse laser therapy devices; the Company s growth strategy; the Company s acquisition
strategy; the Company s sales revenue growth, operational plans, and profitability expectations; the Company s projected fiscal 2013 financial results; and the Company s share repurchase program. These statements are not guarantees of
future performance and actual results may differ materially from those described in these forward-looking statements as a result of a number
of factors. Please see a detailed description of these and other risks contained in our Annual Report on Form 10-K for the fiscal year ended December 29, 2012 filed with the Securities and
Exchange Commission. Forward-looking statements contained in this announcement are made as of this date and will not be updated.
| IRIDEX CONTACT | INVESTOR RELATIONS CONTACT | |
| Jim Mackaness CFO & COO 650-940-4700 | Matt Clawson Allen & Caron 949-474-4500 matt@allencaron.com |
Condensed Consolidated Statements of Operations
(In thousands, except per share
| Three Months Ended | ||||||||
| March 30, 2013 | March 31, 2012 | |||||||
| Total revenues | $ | 8,939 | $ | 8,305 | ||||
| Cost of revenues | 4,708 | 4,319 | ||||||
| Gross profit | 4,231 | 3,986 | ||||||
| Operating expenses: | ||||||||
| Research and development | 996 | 1,182 | ||||||
| Sales and marketing | 1,625 | 1,864 | ||||||
| General and administrative | 1,186 | 1,176 | ||||||
| Proceeds from demutualization of insurance carrier | (473 | ) | ||||||
| Total operating expenses | 3,334 | 4,222 | ||||||
| Income (loss) from continuing operations | 897 | (236 | ) | |||||
| Other expense, net | (18 | ) | (27 | ) | ||||
| Income (loss) from continuing operations before provision for income taxes | 879 | (263 | ) | |||||
| Provision for income taxes | 5 | 2 | ||||||
| Income (loss) from continuing operations, net of tax | 874 | (265 | ) | |||||
| Loss from discontinued operations, net of tax | (162 | ) | ||||||
| Gain on sale of discontinued operations, net of tax | 2,032 | |||||||
| Income from discontinued operations, net of tax | 1,870 | |||||||
| Net income | $ | 874 | $ | 1,605 | ||||
| Net income (loss) per share: | ||||||||
| Basic - | ||||||||
| Continuing operations | $ | 0.10 | ($ | 0.03 | ) | |||
| Discontinued operations | 0.00 | 0.21 | ||||||
| Net income | $ | 0.10 | $ | 0.18 | ||||
| Diluted - | ||||||||
| Continuing operations | $ | 0.09 | ($ | 0.03 | ) | |||
| Discontinued operations | 0.00 | 0.21 | ||||||
| Net income | $ | 0.09 | $ | 0.18 | ||||
| Weighted average shares used in computing net income (loss) per share - basic | 8,511 | 8,933 | ||||||
| Weighted average shares used in computing net income (loss) per share - diluted | 9,802 | 8,933 |
Condensed Consolidated Balance Sheets
| March 30, 2013 | December 29, 2012 | |||||||
| Assets | ||||||||
| Current assets: | ||||||||
| Cash and cash equivalents | $ | 11,581 | $ | 11,901 | ||||
| Accounts receivable, net | 6,031 | 5,480 | ||||||
| Inventories | 8,147 | 8,035 | ||||||
| Prepaid expenses and other current assets | 1,123 | 1,129 | ||||||
| Current assets of discontinued operations | 510 | 510 | ||||||
| Total current assets | 27,392 | 27,055 | ||||||
| Property and equipment, net | 440 | 483 | ||||||
| Other intangible assets, net | 489 | 554 | ||||||
| Goodwill | 533 | 533 | ||||||
| Other long-term assets | 298 | 287 | ||||||
| Total assets | $ | 29,152 | $ | 28,912 | ||||
| Liabilities and Stockholders Equity | ||||||||
| Current liabilities: | ||||||||
| Accounts payable | $ | 1,280 | $ | 2,105 | ||||
| Accrued compensation | 1,442 | 1,563 | ||||||
| Accrued expenses | 1,372 | 1,242 | ||||||
| Accrued warranty | 446 | 453 | ||||||
| Deferred revenue | 943 | 1,004 | ||||||
| Total current liabilities | 5,483 | 6,367 | ||||||
| Long-term liabilities: | ||||||||
| Other long-term liabilities | 542 | 640 | ||||||
| Total liabilities | 6,025 | 7,007 | ||||||
| Stockholders equity: | ||||||||
| Convertible preferred stock | 5 | 5 | ||||||
| Common stock | 95 | 94 | ||||||
| Additional paid-in capital | 39,305 | 38,958 | ||||||
| Accumulated deficit | (16,278 | ) | (17,152 | ) | ||||
| Total stockholders equity | 23,127 | 21,905 | ||||||
| Total liabilities and stockholders equity | $ | 29,152 | $ | 28,912 |